KMT2A and acute lymphoblastic leukemia: Cell cycle analysis of AML and ALL MLL-rearranged cells treated with SB216763, another GSK3 inhibitor with therapeutic properties for pulmonary inflammation and fibrosis (Gurrieri et al., 2010), revealed reduction of G1-S phase progression.